Nathan Connell: What Is The “Mild Equivalent” For Hemophilia A That Is Achieved While on Emicizumab?
Nathan Connell, MD, MPH, FACP, Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital, shared an insightful post on LinkedIn:
”A common question that comes up in hemophilia clinic is: What is the “mild equivalent” for hemophilia A that is achieved while on emicizumab? We know that secondary hemostasis isn’t completely normalized for people taking emicizumab, but patients often ask what their (equivalent) factor VIII level would be if it could be measured. At its most basic, disorders of secondary hemostasis are rooted in an inability to generate thrombin, so thrombin generation assays (TGAs) are theoretically an attractive method to offer a window into the answer for this question; however, differences in TGAs and lack of standardization make it difficult to settle on a single number.
This Haemophilia Journal publication by Daniel Kraemmer and colleagues (including Cihan Ay) highlights the heterogeneity in estimates depending on which TGA parameters are utilized in the analysis, and suggests a conservative estimate is anywhere from 15% – 37%, supporting clinical experience with the therapy but highlighting the need for better methods to assess hemostasis in vivo.”
Read the full article here.
Article: Estimating the Factor VIII-Equivalent Activity of Emicizumab Using Global Assays of Haemostasis
Authors: Daniel Kraemmer , Cihan Ay, Judit Rejtő, Georg Heinze, Peter Quehenberger, Ingrid Pabinger, Oliver Königsbrügge
Stay updated on the latest scientific advancements in the field of hemophilia with Hemostasis Today.
-
Sep 23, 2026, 07:28Isabelle Grenier-Pleau: Targeting Von Willebrand Disease to Transform Women’s Health
-
Sep 23, 2026, 07:07Wolfgang Miesbach: Mechanisms of Liver Injury After Hemophilia A Gene Therapy
-
Sep 23, 2026, 06:24Nicolas Gendron: Everolimus and Venous Thromboembolic Risk in Kidney Transplantation
-
Sep 23, 2026, 06:07Hoori Shahwar: Cerebral Venous Sinus Thrombosis Diagnosis and Management
-
Sep 23, 2026, 06:06Advancing Hemophilia Care and Patient Advocacy in Bangladesh – World Federation of Hemophilia
-
Sep 23, 2026, 05:54Bringing the Global Thrombosis and Haemostasis Community Together in 2027 – ISTH
-
Sep 23, 2026, 04:34David Akande: When Sickle Cell Crises Have No Clear Trigger
-
Sep 23, 2026, 04:13Jean Connors: Safety of Heparin Re-Exposure in Patients with Remote HIT
-
Sep 23, 2026, 04:09Beth Psaila: Applications Now Open for the Gordon Research Conference on Megakaryocytes and Platelets